BlackRock Inc. boosted its position in Bruker Co. (NASDAQ:BRKR) by 7.1% in the 4th quarter, Holdings Channel reports. The firm owned 5,173,860 shares of the medical research company’s stock after buying an additional 341,389 shares during the quarter. BlackRock Inc.’s holdings in Bruker were worth $177,566,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Zions Bancorporation bought a new stake in Bruker in the third quarter worth about $119,000. Bank of Montreal Can lifted its stake in Bruker by 346.7% in the fourth quarter. Bank of Montreal Can now owns 3,708 shares of the medical research company’s stock worth $128,000 after purchasing an additional 2,878 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in Bruker by 7.1% in the second quarter. The Manufacturers Life Insurance Company now owns 5,003 shares of the medical research company’s stock worth $144,000 after purchasing an additional 331 shares during the last quarter. SG Americas Securities LLC bought a new stake in Bruker in the fourth quarter worth about $145,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Bruker by 43.2% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,586 shares of the medical research company’s stock worth $226,000 after purchasing an additional 1,987 shares during the last quarter. 65.52% of the stock is owned by institutional investors and hedge funds.
Several analysts have issued reports on BRKR shares. Cowen reissued a “hold” rating and issued a $35.00 price objective on shares of Bruker in a research note on Thursday, December 21st. BidaskClub downgraded shares of Bruker from a “buy” rating to a “hold” rating in a research note on Saturday, February 10th. Zacks Investment Research downgraded shares of Bruker from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. Evercore ISI started coverage on shares of Bruker in a research note on Wednesday, January 3rd. They issued an “in-line” rating and a $36.00 price objective for the company. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $35.00 price objective on shares of Bruker in a research note on Thursday, December 14th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $32.62.
Shares of Bruker stock opened at $30.03 on Monday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.60 and a current ratio of 2.60. Bruker Co. has a 12 month low of $21.83 and a 12 month high of $36.53. The firm has a market cap of $4,671.56, a P/E ratio of 61.29, a PEG ratio of 1.99 and a beta of 1.16.
Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Thursday, February 8th. The medical research company reported $0.51 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.49 by $0.02. Bruker had a net margin of 4.45% and a return on equity of 26.58%. The firm had revenue of $530.50 million during the quarter, compared to the consensus estimate of $506.74 million. During the same quarter in the previous year, the firm posted $0.46 earnings per share. The company’s revenue was up 12.8% on a year-over-year basis. sell-side analysts expect that Bruker Co. will post 1.37 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 23rd. Investors of record on Tuesday, March 6th will be issued a dividend of $0.04 per share. This represents a $0.16 annualized dividend and a yield of 0.53%. The ex-dividend date is Monday, March 5th. Bruker’s payout ratio is 32.65%.
COPYRIGHT VIOLATION NOTICE: “BlackRock Inc. Has $177.57 Million Holdings in Bruker Co. (BRKR)” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/03/19/blackrock-inc-has-177-57-million-holdings-in-bruker-co-brkr.html.
Bruker Company Profile
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Co. (NASDAQ:BRKR).
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.